- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01461668
Retapamulin for Reducing MRSA Nasal Carriage
The investigators will conduct a randomized placebo-controlled double-blinded study of nasal decolonization with retapamulin vs. placebo for the eradication of MRSA nasal carriage among adult carriers with low-level (MIC 8-256) and high-level mupirocin resistant (MIC >256) strains.
Objectives:
- To determine the percent of intervention vs. control patients with successful MRSA nasal decolonization as determined by bilateral nares swabs following a 5-day twice-a-day regimen of retapamulin.
- To determine the time to decolonization based upon interim and final bilateral nares swabs.
- To determine the acceptability of retapamulin by surveying participants about their experience and adverse events experienced during this study.
The duration of participant follow-up is expected to last up to 7 weeks.
This study will evaluate the safety and effectiveness of Altabax (retapamulin) during decolonization of MRSA carriers with mupirocin-resistant strains, stratified by low-level and high-level resistance to mupirocin. Mupirocin resistance is increasingly common and there is no approved substitute topical agent for decolonization of the MRSA nasal reservoir.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will evaluate the utility of retapamulin, a topical ointment FDA approved for skin infection, as a novel agent for MRSA decolonization and prevention of healthcare-associated MRSA infection. Retapamulin is a first-in-class semi-synthetic pleuromutilin antibiotic that inhibits protein synthesis by interacting with the bacterial ribosome 50S subunit. It received FDA approval in 2007 for the topical treatment of impetigo in adults and pediatric patients.
We propose to evaluate retapamulin as an investigational agent for the nasal decolonization of MRSA carriers whose strains demonstrate low-level and high-level resistance to mupirocin. Mupirocin resistance is increasingly common and there is no approved substitute topical agent for decolonization of the MRSA nasal reservoir.
We will conduct a randomized placebo-controlled double-blinded study of nasal decolonization with retapamulin vs. placebo for the eradication of MRSA nasal carriage among adult carriers with low-level (MIC 8-256) and high-level mupirocin resistant (MIC >256) strains. Randomization will be stratified by low vs high level resistance.
Consenting adult (at least 18 years old) subjects will be randomized to 1% retapamulin or placebo ointment intra-nasally twice a day for 5 days (D1-5) with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance. If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin or placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made. A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
Consenting adult (at least 18 years old)subjects will be given retapamulin or placebo. At the time of recruitment, all subjects will complete a detailed survey administered by trained research staff. This survey will include questions related to self care, home hygiene practices, and known risk factors for MRSA acquisition. Subject follow up will include repeat bilateral nares swabs and follow up surveys related to compliance, experience (side effects/concerns) with the assigned regimen, and ongoing risk factors will occur either during a home visit (or facility visit if the patient is admitted to a hospital or nursing home at the time of the required visit) or at the University of California Irvine (UCI) Institute for Clinical and Translational Science (ICTS), a Clinical and Translational Science Award (CTSA) site which provides clinic visit support for pilot studies.
Outcomes will include successful nares decolonization at the end of the follow up period (D47). We will detail the sequence of clearance or re-colonization based upon the two follow up nares swabs, as well as any adverse events, which are expected to be related to local irritation in a small percent of subjects.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
California
-
Irvine, California, United States, 92617
- University of California, Irivne
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years of age or older
- Have a type of MRSA that is resistant to mupirocin (a drug used to treat MRSA)
Exclusion Criteria:
- Allergic to retapamulin
- Unable to use retapamulin via your nose (i.e. nose surgery, etc.)
- Are pregnant and/or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Retapamulin
Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of retapamulin with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance.
If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (retapamulin) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made.
A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
|
Two times a day for 5 days
Other Names:
|
Placebo Comparator: Placebo
Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of a placebo with follow up bilateral nares swab one week following completion of therapy (~D12) to assess clearance.
If follow up swabs are positive for MRSA, patients will be given a second course of the same agent (placebo) to begin one week following swab collection (~D19-23) so that up to two decolonization attempts will be made.
A final set of bilateral nares swabs will be obtained from all subjects six weeks from the completion of initial treatment (~D47).
|
Two times a day for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Participants With MRSA Clearance
Time Frame: 47 days
|
Proportion of participants with MRSA clearance at the end of the follow up period
|
47 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Susan Huang, MD, MPH, University of California, Irivne - School of Medicine
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OCRT10049
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Methicillin-Resistant Staphylococcus Aureus
-
University of Colorado, DenverAmerican Academy of Family Physicians National Research NetworkCompletedMethicillin-Resistant Staphylococcus AureusUnited States
-
University Hospital, ToulouseCompletedMethicillin-Resistant Staphylococcus AureuS
-
University of Sao PauloUnknownMethicillin Resistant Staphylococcus AureusBrazil
-
University of FloridaRecruitingMethicillin-Resistant Staphylococcus AureusUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedMethicillin-Resistant Staphylococcus AureusFrance
-
University of Lausanne HospitalsCompletedMethicillin-Resistant Staphylococcus Aureus
-
NorthShore University HealthSystemAgency for Healthcare Research and Quality (AHRQ)CompletedMethicillin Resistant Staphylococcus AureusUnited States
-
Pinyo RattanaumpawanUnknownMethicillin-Resistant Staphylococcus AureusThailand
-
Mercy ResearchWithdrawnMethicillin-Resistant Staphylococcus Aureus
-
West Virginia UniversityCompletedMethicillin-Resistant Staphylococcus AureusUnited States
Clinical Trials on Retapamulin
-
Derm Research, PLLCGlaxoSmithKlineCompletedAtopic Dermatitis | Secondary InfectionUnited States
-
Ferrer Internacional S.A.CompletedEfficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoImpetigoGermany, South Africa
-
GlaxoSmithKlineCompletedSkin Infections, BacterialUnited States, Germany, Taiwan, Netherlands, Argentina, Chile, Costa Rica, South Africa, Mexico
-
GlaxoSmithKlineCompletedSkin Infections, BacterialUnited States, South Africa, India, Argentina, Brazil
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
The University of Texas Health Science Center,...GlaxoSmithKlineCompletedFolliculitis | Impetigo | Secondarily Infected Eczema | Minor Soft Tissue InfectionsUnited States
-
GlaxoSmithKlineCompletedSkin Infections, BacterialKorea, Republic of
-
GlaxoSmithKlineCompleted
-
Bay Pines VA Healthcare SystemWithdrawnOrthopedic Procedures | Methicillin-resistant Staphylococcus AureusUnited States
-
Ochsner Health SystemGlaxoSmithKline; Tulane University School of MedicineWithdrawnMethicillin-resistant Staphylococcus AureusUnited States